TY - JOUR AU - Jiménez-Fonseca, Paula AU - Carmona-Bayonas, Alberto AU - Sánchez Lorenzo, Maria Luisa AU - Plazas, Javier Gallego AU - Custodio, Ana AU - Hernández, Raquel AU - Garrido, Marcelo AU - García, Teresa AU - Echavarría, Isabel AU - Cano, Juana María AU - Rodríguez Palomo, Alberto AU - Mangas, Monserrat AU - Macías Declara, Ismael AU - Ramchandani, Avinash AU - Visa, Laura AU - Viudez, Antonio AU - Buxó, Elvira AU - Díaz-Serrano, Asunción AU - López, Carlos AU - Azkarate, Aitor AU - Longo, Federico AU - Castañón, Eduardo AU - Sánchez Bayona, Rodrigo AU - Pimentel, Paola AU - Limón, Maria Luisa AU - Cerdá, Paula AU - Álvarez Llosa, Renata AU - Serrano, Raquel AU - Lobera, Maria Pilar Felices AU - Alsina, María AU - Hurtado Nuño, Alicia AU - Gómez-Martin, Carlos PY - 2016 DO - 10.1007/s10120-016-0639-8 UR - http://hdl.handle.net/10668/10422 T2 - Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association AB - Trastuzumab significantly improves overall survival (OS) when added to cisplatin and fluoropyrimidine as a treatment for HER2-positive advanced gastric cancers (AGC). The aim of this study was to evaluate the impact of the gradual implementation of... LA - en KW - Gastric cancer KW - HER2 testing KW - Personalized medicine KW - Quality of care KW - Trastuzumab KW - Adult KW - Aged KW - Aged, 80 and over KW - Antineoplastic Combined Chemotherapy Protocols KW - Biomarkers, Tumor KW - Female KW - Humans KW - Kaplan-Meier Estimate KW - Male KW - Middle Aged KW - Prognosis KW - Proportional Hazards Models KW - Receptor, ErbB-2 KW - Spain KW - Stomach Neoplasms KW - Trastuzumab TI - Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. TY - research article VL - 20 ER -